We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

114 hedge funds and large institutions have $1.43B invested in Audentes Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 30

39% more call options, than puts

Call options by funds: $2.85M | Put options by funds: $2.05M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

4% more capital invested

Capital invested by funds: $1.37B → $1.43B (+$56.1M)

7% less funds holding

Funds holding: 123 → 114 (-9)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

Holders
114
Holders Change
-9
Holders Change %
-7.32%
% of All Funds
2.61%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
11
Increased
44
Reduced
30
Closed
20
Calls
$2.85M
Puts
$2.05M
Net Calls
+$808K
Net Calls Change
+$2.5M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$42.1M
2
NC
Nexthera Capital
New York
+$11.2M
3
UBS AM
UBS AM
Illinois
+$9.44M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$7.08M
5
CC
Casdin Capital
New York
+$6.52M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$25.2M
2
DM
Deerfield Management
New York
-$20.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.2M
4
O
OrbiMed
New York
-$16.2M
5
Millennium Management
Millennium Management
New York
-$12.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
76
Barclays
United Kingdom
$788K +$561K +15,039 +310%
ProShare Advisors
77
ProShare Advisors
Maryland
$760K -$17.2K -462 -2%
TAM
78
Tocqueville Asset Management
New York
$663K – – –
PPA
79
Parametric Portfolio Associates
Washington
$601K -$46.3K -1,242 -8%
MIM
80
MetLife Investment Management
New Jersey
$593K – – –
PIM
81
Partner Investment Management
California
$548K +$359K +9,619 +227%
MSL
82
Mackay Shields LLC
New York
$546K +$104K +2,800 +25%
VOYA Investment Management
83
VOYA Investment Management
Georgia
$490K – – –
VEA
84
Virtus ETF Advisers
New York
$480K -$324K -8,679 -42%
Principal Financial Group
85
Principal Financial Group
Iowa
$456K +$234K +6,269 +120%
MLICM
86
Metropolitan Life Insurance Company (MetLife)
New York
$419K – – –
DekaBank Deutsche Girozentrale
87
DekaBank Deutsche Girozentrale
Germany
$418K -$11.2K -300 -3%
State Board of Administration of Florida Retirement System
88
State Board of Administration of Florida Retirement System
Florida
$390K +$43.2K +1,160 +13%
UBS Group
89
UBS Group
Switzerland
$350K -$25.3K -678 -7%
BAM
90
Belpointe Asset Management
Nevada
$297K – – –
ARTA
91
A.R.T. Advisors
New York
$279K -$144K -3,857 -35%
Legal & General Group
92
Legal & General Group
United Kingdom
$195K – – –
Mitsubishi UFJ Asset Management
93
Mitsubishi UFJ Asset Management
Japan
$170K +$160K +4,297 New
AIP
94
Ameritas Investment Partners
Nebraska
$99K – – –
Pacer Advisors
95
Pacer Advisors
Pennsylvania
$99K +$93K +2,494 New
TIM
96
Tortoise Investment Management
New York
$98K – – –
Canada Life
97
Canada Life
Manitoba, Canada
$96K – – –
Simplex Trading
98
Simplex Trading
Illinois
$88K +$83.8K +2,247 New
Zurich Cantonal Bank
99
Zurich Cantonal Bank
Switzerland
$79K – – –
SO
100
STRS Ohio
Ohio
$71K – – –
2 3
4
5 6

BOLD Hedge Fund Activity: Q3 2018 in Review

114 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2018, worth a combined $1.43B — up 4.1% from $1.37B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BOLD and 11 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 44 added.

The largest buyer was PFM Health Sciences, adding an estimated $42.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $25.2M sold.

  • 114 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2018, down from 123 in Q2 2018.
  • Funds reported $1.43B of Audentes Therapeutics, Inc stock for Q3 2018, up 4.1% quarter-over-quarter.
  • 11 funds opened new Audentes Therapeutics, Inc positions in Q3 2018 and 20 closed out, a net change of -9 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2018 was PFM Health Sciences, an estimated $42.1M added.
  • The largest Audentes Therapeutics, Inc seller in Q3 2018 was Perceptive Advisors, an estimated $25.2M sold.

Based on aggregated 13F filings for Q3 2018.